Amgen’s second quarter results reflected broad-based portfolio momentum, with management crediting double-digit growth in key ...

Enbrel, a mainstay biologic in the inflammation category, fell 4% overall, with net selling price down 22%. Amgen attributed ...

"We know they have the resources and the position to end their relationship with Marshall BioResources." ...

Hackers recently accessed Amgen’s cloud environment, stealing sensitive patient health information and proprietary company ...

The recommendation is based on data from the Phase III VESALIUS-CV trial, which involved more than 12,000 patients.

As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular ...

Three days ago, on August 4, Amgen ( AMGN) released another strong earnings report. Its revenue was $10.1 billion, up 16.6% ...

Amgen Inc. experienced a cyber incident that involved the theft of patient information and proprietary data stored in cloud ...

Genome Valley offers strong scientific expertise and infrastructure, and the new facility will complement Amgen's existing technology and innovation site in Hyderabad. Together, these sites will ...

Amgen Q2 earnings preview: estimates, revenue outlook, Repatha/Tezspire growth, legacy declines & MariTide obesity pipeline ...

Amgen is expanding its footprint in India with an R&D center in Hyderabad, the latest effort from the California company to boost its research facilities. | Amgen is expanding its footprint in India ...